Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 4/20 | 0.44 |
| ▸ | HTR2C | P28335 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8190758 | 0.86 | HDAC3 (0.53) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4777998 | 0.85 | ATM (0.66) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL3299243 | 0.82 | ATM (0.50) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5755454 | 0.78 | GAA (0.53) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5755449 | 0.78 | GAA (0.53) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8209416 | 0.77 | AHR (0.47) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL11730476 | 0.76 | MAOA (0.68) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL28114236 | 0.75 | HDAC3 (0.50) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1149700 | 0.75 | EDNRB (0.40) | MEN1KMT2AHTTALDH1A1 | |
| SCHEMBL19885497 | 0.74 | AHR (0.57) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1228337-C | Carbamic acid derivs. and their use as metabotropic glutamate receptor ligands | HOFFMANN LA ROCHE (CH) | 2005-11-23 | — | — | CN | disclosed |
| US-6803381-B1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS, ACTING AS ANTAGONISTS OR AGONISTS | HOFFMANN-LA ROCHE INC. | 2004-10-12 | — | — | US | disclosed |
| US-6596743-B2 | Control or prevention of acute and/or chronic neurological disorders | HOFFMANN-LA ROCHE INC. | 2003-07-22 | — | — | US | disclosed |
| US-6462198-B1 | USED IN THE CONTROL OR PREVENTION OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS RESTRICTED BRAIN FUNCTION CAUSED BY BYPASS OPERATIONS OR TRANSPLANTS, POOR BLOOD SUPPLY TO THE BRAIN, SPINAL CORD INJURIES, HEAD INJURIES, HYPOXIA, | HOFFMANN-LA ROCHE INC. | 2002-10-08 | — | — | US | disclosed |
| US-20020091150-A1 | Carbamic acid derivatives | BLEICHER KONRAD (DE) | 2002-07-11 | — | — | US | disclosed |
| CN-1347406-A | Carbamic acid derivs. and their use as metabotropic glutamate receptor ligands | HOFFMANN LA ROCHE (CH) | 2002-05-01 | — | — | CN | disclosed |
| EP-1171423-A1 | CARBAMIC ACID DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000063166-A1 | CARBAMIC ACID DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091150-A1 | Carbamic acid derivatives | CHRM1, CHRNA2, CHRM2 | HDAC3 533/4885HDAC4 852/4885HDAC1 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.